Disease · MONDO_0006939

pyelonephritis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. pyelonephritis. Diseases, record MONDO_0006939. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006939

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: pyelonephritis; Open Targets
Open Targets ID: MONDO_0006939; Open Targets
Other names: kidney infection; Open Targets
Disease Ontology: DOID:11400; Disease Ontology
MeSH: D011704; MeSH
NCI Thesaurus: C34965; NCI Thesaurus
Highest stage of its drugs: Approval, for 15 of its 34 drugs, from DailyMed, EMA Human Drugs, FDA and PMDA; Open Targets

Drugs34

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
TAZOBACTAM	CHEMBL404	Small molecule	Approval	PMDA	4	2	2	Drugs and targets
DORIPENEM	CHEMBL491571	Small molecule	Approval	DailyMed	3	2	2	Drugs and targets
CIPROFLOXACIN	CHEMBL8	Small molecule	Approval	DailyMed	9	1	1	Drugs and targets
CEFTAZIDIME	CHEMBL44354	Small molecule	Approval	DailyMed and PMDA	3	1	1	Drugs and targets
CEFEPIME	CHEMBL186	Small molecule	Approval	EMA Human Drugs	2	1	1	Drugs and targets
AZTREONAM	CHEMBL158	Small molecule	Approval	DailyMed	5	0	0	Drugs and targets
CIPROFLOXACIN HYDROCHLORIDE	CHEMBL1202	Small molecule	Approval	DailyMed	4	0	0	Drugs and targets
AVIBACTAM SODIUM	CHEMBL2107817	Small molecule	Approval	DailyMed and PMDA	2	0	0	Drugs and targets
CEFTOLOZANE SULFATE	CHEMBL1213250	Small molecule	Approval	PMDA	1	0	0	Drugs and targets
ENMETAZOBACTAM	CHEMBL4458276	Small molecule	Approval	EMA Human Drugs	1	0	0	Drugs and targets

1 to 10 of 34

See all 34 drugs

Targets7

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
SLC5A2	Sodium/glucose cotransporter 2	2	Sodium/glucose cotransporter 2 inhibitor	Unknown	https://conductscience.org/library/genes/6524	Drugs and targets
DPP4	Dipeptidyl peptidase 4	1	Dipeptidyl peptidase IV inhibitor	Unknown	https://conductscience.org/library/genes/1803	Drugs and targets
DRD2	D(2) dopamine receptor	1	Dopamine D2 receptor antagonist	Phase 2	https://conductscience.org/library/genes/1813	Drugs and targets
HTR2A	5-hydroxytryptamine receptor 2A	1	Serotonin 2a (5-HT2a) receptor antagonist	Phase 2	https://conductscience.org/library/genes/3356	Drugs and targets
SLC22A11	Solute carrier family 22 member 11	1	Solute carrier family 22 member 11 inhibitor	Phase 3	https://conductscience.org/library/genes/55867	Drugs and targets
SLC22A6	Solute carrier family 22 member 6	1	Solute carrier family 22 member 6 inhibitor	Phase 3	https://conductscience.org/library/genes/9356	Drugs and targets
SLC22A8	Organic anion transporter 3	1	Solute carrier family 22 member 8 inhibitor	Phase 3	https://conductscience.org/library/genes/9376	Drugs and targets

Trials16

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03357614	Sulopenem Followed by Sulopenem-etzadroxil/Probenecid vs Ertapenem Followed by Cipro for Complicated UTI in Adults	Phase 3	1,395	2020-12-29	Complicated Urinary Tract Infections	PROBENECID, SULOPENEM, SULOPENEM ETZADROXIL	Its record names the disease	ClinicalTrials.gov
NCT01345929	Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Levofloxacin in Complicated Urinary Tract Infection, Including Pyelonephritis	Phase 3	558	2015-01-15	Complicated Urinary Tract Infection, Pyelonephritis	CEFTOLOZANE, LEVOFLOXACIN, TAZOBACTAM	Its record names the disease	ClinicalTrials.gov
NCT03230838	MK-7625A Versus Meropenem in Pediatric Participants With Complicated Urinary Tract Infection (cUTI) (MK-7625A-034)	Phase 2	134	2021-12-01	Complicated Urinary Tract Infection, Pyelonephritis	CEFTOLOZANE, TAZOBACTAM	Its record names the disease	ClinicalTrials.gov
NCT00921024	Safety and Efficacy of IV CXA-101 and IV Ceftazidime in Patients With Complicated Urinary Tract Infections	Phase 2	129	2015-01-15	Complicated Urinary Tract Infection	CEFTAZIDIME, CEFTOLOZANE	Its record names the disease	ClinicalTrials.gov
NCT02728089	Study of Ceftolozane/Tazobactam (MK-7625A) in Japanese Participants With Uncomplicated Pyelonephritis and Complicated Urinary Tract Infection (MK-7625A-014)	Phase 3	115	2018-09-19	Urinary Tract Infection (UTI), Complicated Urinary Tract Infection, Pyelonephritis, Uncomplicated Pyelonephritis	CEFTOLOZANE	Its record names the disease	ClinicalTrials.gov
NCT02302092	An Efficacy and Safety of Flomoxef Versus Cefepime in the Treatment of Participants With Urinary Tract Infections	Phase 3	13	2017-10-27	Urinary Tract Infection	CEFEPIME, FLOMOXEF	Its record names the disease	ClinicalTrials.gov
NCT00229021	Doripenem in the Treatment of Complicated Lower Urinary Tract Infection or Pyelonephritis	Phase 3	741		Urinary Tract Infections, Pyelonephritis	DORIPENEM	Its record names the disease	ClinicalTrials.gov
NCT00210990	Doripenem in the Treatment of Complicated Lower Urinary Tract Infection or Pyelonephritis	Phase 3	403		Urinary Tract Infections, Pyelonephritis	DORIPENEM	Its record names the disease	ClinicalTrials.gov
NCT01406275	Special Drug Use Investigation for CLAVAMOX® (Amoxicillin/Clavulanate) Pediatrics Dry Syrup (Every Indication Excluded Otitis Media)		363		Otitis Maedia	AMOXICILLIN, CLAVULANIC ACID	Its record names the disease	ClinicalTrials.gov
NCT06144060	A Trial of Intravenous HRS-8427 in the Treatment of Adults With Complicate Urinary Tract Infection, Including Acute Pyelonephritis	Phase 2	126		Patients With Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP)	IMIPENEM	Its record names the disease	ClinicalTrials.gov

1 to 10 of 16

See all 16 trials

Comparisons in its trials11

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Sulopenem vs Ertapenem: deaths from any cause	2 of 697	0 of 698	1,395	NCT03357614	Trial comparisons
Sulopenem vs Ertapenem: serious adverse events	14 of 697	6 of 698	1,395	NCT03357614	Trial comparisons
CXA-201 as Treatment for cUTI vs Levofloxacin as Treatment for cUTI: serious adverse events	15 of 533	18 of 535	1,068	NCT01345929	Trial comparisons
Sulopenem vs Ertapenem: Percentage of Participants With Overall Success	301 of 444	325 of 440	884	NCT03357614	Trial comparisons
Sulopenem vs Ertapenem: Percentage of Participants With Microbiologic Success	316 of 444	343 of 440	884	NCT03357614	Trial comparisons
Ceftolozane/Tazobactam vs Meropenem: deaths from any cause	0 of 101	0 of 33	134	NCT03230838	Trial comparisons
Ceftolozane/Tazobactam vs Meropenem: Number of Participants Discontinuing Study Therapy Due to AE	1 of 100	0 of 33	133	NCT03230838	Trial comparisons
Ceftolozane/Tazobactam vs Meropenem: Number of Participants With ≥1 Adverse Events (AEs)	59 of 100	20 of 33	133	NCT03230838	Trial comparisons
Ceftolozane/Tazobactam vs Meropenem: serious adverse events	3 of 100	2 of 33	133	NCT03230838	Trial comparisons
CXA-101 vs Ceftazidime: serious adverse events	1 of 85	0 of 42	127	NCT00921024	Trial comparisons

1 to 10 of 11

See all 11 comparisons in its trials

Papers from its trials35

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
36689671	RESULT	1	PubMed
26603304	RESULT	1	PubMed
26414659	RESULT	1	PubMed
25808018	RESULT	1	PubMed
25712752	RESULT	1	PubMed
25220556	RESULT	1	PubMed
24080664	RESULT	1	PubMed
23642005	RESULT	1	PubMed
23153962	RESULT	1	PubMed
22839761	RESULT	1	PubMed

1 to 10 of 35

See all 35 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0006939

GET https://conductscience.org/api/diseases/v1/MONDO_0006939/drugs?page=2

API reference For AI assistants